PR070/#391 Phase I trial of tilvestamab, a function-blocking antibody inhibiting AXL, in platinum-resistant/refractory high grade serous ovarian cancer (PROC)
David S.P. Tan(National University of Singapore), Line Bjørge(Haukeland University Hospital), Tuan Zea Tan(National University Cancer Institute, Singapore), David Micklem(BerGenBio (Norway)), Thomas Talbot(Hammersmith Hospital), Akil Jackson(BerGenBio (Norway)), Jae‐Weon Kim(Seoul National University), Sarah P. Blagden(Churchill Hospital), Rebecca Kristeleit(Guy's and St Thomas' NHS Foundation Trust), Byoung Gie Kim(Samsung Medical Center), David J. Pinato(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Jung-Yun Lee(Yonsei University), Charlie Gourley(Edinburgh Cancer Research)
Cited by 1
Related Papers
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer
|JAMA Oncology|2019|582
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
|The Lancet Oncology|2021|401